Verici Dx PLC on Monday celebrated the publication of data from its Tutivia trial, which demonstrated the efficacy of the post-transplant test, in the American Journal of Transplantation.

Verici is a Cardiff, Wales-based company, which develops advanced clinical diagnostics for organ transplant. Shares in the firm were up 13% at 8.33 pence each in London on Monday morning.

Tutivia is Verici’s post-transplant blood test. It calculates the risk of ‘all forms of acute rejection’, and was commercially launched in January of this year to improve clinical care for kidney transplant patients.

Data from the study showed that Tutivia delivered a ‘significant improvement’ in biomarker offerings, particularly early post-transplant when other biomarkers are contraindicated or less informative.

According to Verici, these results were ‘particularly noteworthy’, given that the study used a generalised ‘all-comers’ patient population, rather than a specific subgroup. It also examined performance in both the for-cause and surveillance settings.

Publication following peer review, as Verici emphasised, is a ‘crucial step’ in the commercialisation of a new product. It could also help the firm to get a local coverage determination for Medicare reimbursement, which would give Medicare patients access to the test.

‘We are already seeing growing clinical interest, and as this publication is key in the application for LCD coverage, we anticipate an accelerated adoption of Tutivia within the medical community, marking a significant step forward in enhancing diagnostic accuracy and post-transplant patient care,’ said Chief Operating Officer Patti Connolly.

Copyright 2023 Alliance News Ltd. All Rights Reserved.